aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Fisher Wallace Laboratories, founded in 2007 by Charles Avery Fisher and Martin Wallace, is headquartered in New York City. The company specializes in cranial electrotherapy stimulation (CES) devices designed to treat mental health conditions such as anxiety, depression, and insomnia. Their flagship product, the Fisher Wallace Stimulator, aims to provide rapid and safe mental healthcare. Fisher Wallace Labs is committed to increasing access to effective mental health treatments and is working towards commercializing their next-generation wearable device, OAK, by 2025.
Notable figures associated with the company include co-founders Charles Avery Fisher, son of electronics pioneer Avery Fisher, and Martin Wallace. The company has been recognized in Inc. magazine's "Inc. 5000" list, ranking #983 in 2014 and #1447 in 2015. Fisher Wallace Laboratories has made significant strides in validating and commercializing its technology, contributing positively to the mental health sector by offering innovative treatment options for neuropsychiatric and cognitive disorders.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
CES Devices
Technology
Electrotherapy
Tags
Healthtech
Model Types
Hardware
Revenue Type(s)
Recurring
Customer Type(s)
Consumers
Geographic Exposure
United States
When was Fisher Wallace Laboratories founded?
Fisher Wallace Laboratories was founded in 2007.
Where is Fisher Wallace Laboratories’s headquarters located?
Fisher Wallace Laboratories’s headquarters is located in New York City, NY, US.
When was Fisher Wallace Laboratories’s last funding round?
Fisher Wallace Laboratories’s most recent funding round was for $2.5M (USD) in March 2022.
How many employees does Fisher Wallace Laboratories have?
Fisher Wallace Laboratories has 375 employees as of Feb 5, 2024.
How much has Fisher Wallace Laboratories raised to-date?
As of July 05, 2023, Fisher Wallace Laboratories has raised a total of $8.3M (USD) since Mar 29, 2022.
Add Comparison
Total Raised to Date
$8.3M
USD
Last Update Mar 29, 2022
Last Deal Details
$2.5M
USD
Mar 29, 2022
Series Unknown
Total Employees Over Time
375
As of Feb 2024
Fisher Wallace Laboratories Address
630 Flushing Ave
New York City,
New York
11206
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts